Findings from several clinical trials suggest cannabidiol (CBD) can mitigate treatment-resistant seizures. One trial from the Massachusetts General Hospital analyzed the effects of CBD treatment over the course of a year in 18 patients who suffered from refractory epileptic seizures as a result of tuberous sclerosis complex (TSC). They found CBD reduced the median weekly seizure frequency by half, and that the treatment was well-tolerated. A case reports found in Frontiers of Pharmacology found CBD resulted in complete seizure remission in a seven-year-old boy who suffered from Dravet syndrome, as well as a ten-year-old girl with refractory epilepsy.
A trial from the Children's Hospital of Philadelphia and Texas Children's Hospital assessed the use of Epidiolex, an oral pharmaceutical medication composed of extracted CBD, in seven children with persistent refractory seizures due to febrile infection-related epilepsy syndrome (FIRES). In six of the patients, seizure frequency and duration was reduced, and the participants also eliminated their use of four anti-epileptic drugs. Another trial found patients diagnosed with Lennox-Gastaut Syndrome experienced reduced seizure frequency as a result of Epidiolex use, and they tolerated the medication well.
This information has been provided by the Daily Chronic and approved by our Chief Medical Officer.